Impact case studies
Mpox treatment and drug resistance
People living with HIV have been disproportionately affected by Mpox, often experiencing more severe illness and complications during treatment.
In early 2025, clinicians encountered a life-threatening case in a patient with advanced HIV where standard antiviral therapy failed. Researchers at the MRC-University of Glasgow Centre for Virus Research uncovered the emergence of drug-resistant mpox strains during treatment, highlighting a growing challenge for global Mpox control. This case highlights the urgent need for improved surveillance, alternative treatment options, and sustained investment in antiviral research.
What happens when the frontline treatment for mpox stops working? In this video, researchers from the MRC-University of Glasgow Centre for Virus Research discuss a rare but serious case of drug-resistant mpox, what it means for people living with HIV, and why monitoring resistance is critical for future outbreak control.